Shares of Suven Life Sciences Limited surged 8% on January 8, reaching ₹139.00 during the trading session. The sharp rise comes after the company announced the dosing of the first subjects in a Phase-1 clinical trial for SUVN-I6107, a muscarinic M1 positive allosteric modulator (M1 PAM) targeting cognitive disorders.
Key Stock Highlights:
- Previous Close: ₹126.38
- Current Price: ₹139.00 (+₹12.62)
- Day Range: ₹123.44 – ₹139.00
- 52-Week Range: ₹82.95 – ₹169.30
- Market Cap: ₹29.78 billion
The trial is being conducted under the U.S. FDA’s Investigational New Drug (IND) approval. It involves a randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of SUVN-I6107.
Suven Life Sciences Share Price history
| Day | Open | Close | Change % |
|---|---|---|---|
|
Tue, Jan 7 2025
|
₹123.95
|
₹126.38
|
|
|
Mon, Jan 6 2025
|
₹129.77
|
₹122.46
|
-4.98%
|
|
Fri, Jan 3 2025
|
₹130.15
|
₹128.88
|
|
|
Thu, Jan 2 2025
|
₹128.20
|
₹128.22
|
|
|
Wed, Jan 1 2025
|
₹126.50
|
₹127.92
|
|
|
Tue, Dec 31 2024
|
₹125.92
|
₹127.92
|
|
|
Mon, Dec 30 2024
|
₹135.59
|
₹126.24
|
-1.62%
|
|
Fri, Dec 27 2024
|
₹132.90
|
₹128.32
|
-2.09%
|
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
